Blood dose optimization study for blood disorders
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests different doses of treatments for people with blood disorders. It aims to find the best dose to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with a blood or bone marrow disorder.
- You are able to give informed consent.
- You are expected to live at least 3 more months.
- You meet any additional criteria for a specific part of the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a new drug, BL-M24D1, for people with multiple myeloma or other blood cancers that have come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
This trial tests a new treatment for people with advanced blood cancers like leukemia or lymphoma that have come back or not improved. The goal is to see if the drug can help control the disease.
This trial tests a drug called teclistamab for people with Waldenström's macroglobulinemia that has come back or not responded to other treatments. Teclistamab is a type of immunotherapy that helps your immune system find and attack cancer cells.
Hear when a new Waldenstrom Macroglobulinaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.